RXI-109
Sponsors
RXi Pharmaceuticals, Corp.
Conditions
Age-related Macular DegenerationCicatrixHypertrophic ScarKeloidScar PreventionSubfoveal Choroidal NeovascularizationSubretinal FibrosisSubretinal Scarring
Phase 1
Evaluation of the Safety, Pharmacokinetics, and Preliminary Effect on Scar Formation by RXI-109
CompletedNCT01640912
Start: 2012-06-30End: 2014-05-31Updated: 2014-09-17
Evaluation of Safety, PK, and Preliminary Effects on Scar Formation of Multiple Intradermal Administrations of RXI-109
CompletedNCT01780077
Start: 2012-12-31End: 2014-11-30Updated: 2014-12-03
Evaluating RXI-109 to Reduce the Progression of Subretinal Fibrosis in Subjects With NVAMD
NCT02599064
Start: 2015-11-30End: 2018-05-31Target: 9Updated: 2018-02-26
Phase 2
A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery in Healthy Adults
CompletedNCT02030275
Start: 2013-11-30End: 2016-06-30Updated: 2016-06-21
A Study to Evaluate the Effectiveness and Safety of RXI-109 on the Outcome of Keloid Excision Surgery in Healthy Adults
CompletedNCT02079168
Start: 2014-03-31End: 2016-03-31Updated: 2016-06-14
A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Revised Hypertrophic Scars
NCT02246465
Start: 2014-07-31End: 2018-03-31Target: 40Updated: 2018-02-23